Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections.

Antimicrobial Agents and Chemotherapy
T W FeltonThomas P Lodise

Abstract

While extended infusions of piperacillin-tazobactam (TZP) are increasingly used in practice, the effect of infusion on the pharmacokinetic (PK) profile of TZP has not been widely assessed. To assess its effect on the pharmacokinetic profile of TZP, seven serum samples were collected from 11 hospitalized patients who received 3.375 g TZP intravenously for 4 h every 8 h. Population pharmacokinetic models were fit to the PK data utilizing first-order, Michaelis-Menten (MM), and parallel first-order/MM clearance. A population PK model with first-order clearance was fit to the tazobactam PK data. Monte Carlo simulations (MCSs) were used to determine the most effective administration schedule to ensure that free piperacillin concentrations were above the MIC for at least 50% of the dosing interval (50% fT>MIC) and to quantify the extent of the nonlinear clearance. The model incorporating parallel linear/MM clearance best fit the piperacillin PK data. The MCSs demonstrated that approximately 50% of the administered piperacillin is cleared by the nonlinear clearance mechanism. The results of the MCSs also revealed that more intensive TZP extended infusion dosing schemes (3.375 to 4.5 g intravenously [3-h infusion] every 6 h) than those...Continue Reading

References

Mar 1, 1979·Computer Programs in Biomedicine·D Z D'Argenio, A Schumitzky
Jan 1, 1982·Chemotherapy·T Bergan, J D Williams
Jan 1, 1993·The Journal of Antimicrobial Chemotherapy·F Sörgel, M Kinzig
Feb 10, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W A Craig
May 29, 1999·Antimicrobial Agents and Chemotherapy·B Auclair, M P Ducharme
Aug 26, 2003·Antimicrobial Agents and Chemotherapy·Vincent H TamG L Drusano
Mar 20, 2004·Nature Reviews. Microbiology·George L Drusano
Sep 2, 2008·Nephron. Clinical Practice·Heidi J CoxEric S Kilpatrick
Oct 16, 2008·Anaesthesia and Intensive Care·O Fuster-LluchM Lizán-García
Feb 25, 2009·Critical Care Medicine·Jason A Roberts, Jeffrey Lipman
Mar 2, 2010·International Journal of Antimicrobial Agents·Jason A RobertsJeffrey Lipman
Mar 17, 2010·International Journal of Antimicrobial Agents·Nicolas BlondiauxMicheline Roussel-Delvallez
Jul 20, 2010·Expert Opinion on Drug Metabolism & Toxicology·Yoshiro HayashiJeffrey Lipman
Sep 18, 2010·The European Respiratory Journal·J RelloUNKNOWN EU-VAP/CAP Study Group
Nov 3, 2010·British Journal of Clinical Pharmacology·Jürgen B BulittaNicholas H G Holford

❮ Previous
Next ❯

Citations

Sep 21, 2013·Intensive Care Medicine·Andrew A UdyJeffrey Lipman
Aug 28, 2013·Expert Review of Anti-infective Therapy·Dana R Bowers, Vincent H Tam
Nov 6, 2015·The Journal of Antimicrobial Chemotherapy·Mercedes Delgado-ValverdeUNKNOWN REIPI/GEIH-SEIMC BACTERAEMIA-MIC group
Apr 5, 2016·Critical Care : the Official Journal of the Critical Care Forum·Johannes ZanderMichael Zoller
Jul 6, 2014·Diagnostic Microbiology and Infectious Disease·T W FeltonJ A Roberts
Feb 14, 2015·Clinics in Perinatology·Leslie C Pineda, Kevin M Watt
Jul 31, 2016·Clinical Therapeutics·Jacob K Johnson, Matthew M Laughon
Nov 1, 2016·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·H BaoZ Yan
Jan 24, 2013·The Annals of Pharmacotherapy·Heather M ArnoldMarin H Kollef
Mar 7, 2018·Antimicrobial Agents and Chemotherapy·Maria Goul AndersenKristina Öbrink-Hansen
Jun 25, 2014·Hospital Pharmacy·Megan L MaddoxRhonda J Hammerquist
Jul 11, 2018·Antimicrobial Agents and Chemotherapy·Alexandra JacobsMaya Hites
Mar 13, 2014·Antimicrobial Agents and Chemotherapy·Michael Cohen-WolkowiezP Brian Smith
Jul 15, 2016·Clinical Microbiology Reviews·Mordechai GrupperDavid P Nicolau
Sep 4, 2018·British Journal of Clinical Pharmacology·Dagan O LonsdaleJoseph F Standing
Oct 17, 2013·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Dana R BowersAmy N Schilling
Jun 14, 2014·Clinical Pharmacology and Therapeutics·T W FeltonW W Hope
Aug 21, 2019·Antimicrobial Agents and Chemotherapy·Céline ThibaultJulie Autmizguine
Apr 8, 2017·The Journal of Antimicrobial Chemotherapy·Pieter A J G De CockPeter De Paepe
Sep 27, 2018·The Journal of Antimicrobial Chemotherapy·Ryan L CrassThomas P Lodise
May 28, 2019·The Journal of Pharmacy and Pharmacology·Kayode OgungbenroRobert Duncombe
Aug 2, 2017·Future Microbiology·Nazario D Rivera-ChaparroRachel G Greenberg
Sep 10, 2019·Expert Opinion on Pharmacotherapy·Jason M Pogue, Emily L Heil
Oct 28, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A HendersonUNKNOWN MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN)
Nov 4, 2020·Antimicrobial Agents and Chemotherapy·Marco M CustodioRenee-Claude Mercier

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.